Officer Marshall Fordyce Files Intent to Sell $2.8M in Stock
VERA has more than doubled off its 52-week low of $19.066.
Summary
An officer and director of Vera Therapeutics has filed an intent to sell $2.84 million worth of stock, continuing a pattern of executive share dispositions.
Key Events · Ownership and Investor Activity · VERA
-
Continuation of Prior Sales
This proposed sale follows previous dispositions by Fordyce totaling 41,451 shares for $1.69 million over the last three months, which were executed under a 10b5-1 plan.
-
Shares from Option Exercise
The shares to be sold were acquired through the exercise of stock options, indicating a monetization of compensation rather than a direct market sale of existing holdings.
-
Ongoing Executive Distribution
This filing contributes to a pattern of executive share distribution, with net insider selling of $1.69 million in open-market transactions over the past 90 days.
Analysis · VERA · Life Sciences
Marshall Fordyce, an officer and director, has filed a Form 144 indicating an intent to sell 74,000 shares of common stock, valued at approximately $2.84 million. This follows previous sales by Fordyce totaling $1.69 million over the past three months, which were part of a 10b5-1 plan. While these sales are likely pre-planned and related to option exercises for liquidity, the cumulative distribution by a key executive adds to selling pressure, especially given the company's recent cash burn reported in Q1 2026.
At the time of this filing, VERA was trading at $38.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $19.07 to $56.05. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.